相关实验视频
Updated: Jun 21, 2025
05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
4.5K
一个致命的后果:阿米奥达龙诱导的多器官毒性
Mohammed Al-Hiari1, Ma'in Abumuhfouz2, Leen Kayali1
1Internal Medicine, Marshall University Joan C. Edwards School of Medicine, Huntington, USA.
Cureus
|July 15, 2024
概括
这份病例报告强调了阿米奥达龙毒性导致的致命结果,该病例发生在一个患有多种并发病症的老年男性身上. 在高风险患者中,提高对阿米奥达龙不良事件的警,特别是肺和甲状腺功能障碍,至关重要.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 内分泌学 在内分泌学.
背景情况:
- 阿米奥达龙是一种广泛用于心房动 (AF) 的抗心律失常剂.
- 高剂量的阿米奥达龙 (≥400毫克/天) 与不良事件的风险增加有关.
- 患有心血管并发症的老年患者特别容易受到药物毒性的影响.
研究的目的:
- 报告一种罕见的严重,致命的阿米奥达龙毒性病例.
- 强调认识到阿米奥达龙诱导的肺毒性和甲状腺毒性的重要性.
- 倡导在高危人群中增加临床怀疑和监测.
主要方法:
- 一个70岁的男性患有冠状动脉疾病和外周动脉疾病的案例介绍.
- 详细的临床过程包括手术干预,新发性AF和阿米奥达龙治疗.
- 诊断工作包括成像,心声学,支气管与支气管支气管洗的支气管镜以及实验室测试 (肝酶,甲状腺功能).
主要成果:
- 患者出现了渐进性呼吸不全,扩散地玻璃不透明,间歇性加厚,以及急性呼吸困扰综合征 (ARDS).
- 支气管支气管洗揭示了扩散性支气管出血 (DAH) 淋巴细胞占主导地位和负面的感染后果.
- 实验室发现表明2型阿米奥达龙诱导的甲状腺毒性和肝酶升高.
- 尽管接受了治疗,但患者的病情恶化,导致死亡.
结论:
- 致命的阿米奥达龙毒性,虽然很少见,但需要提高临床意识.
- 患有心肺并发症的老年男性有严重的阿米奥达不良事件的显著风险.
- 在阿米奥达龙治疗期间,密切监测肺功能,实验室检查和成像是必不可少的.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
964
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
964
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
01:26Toxic Reactions: Overview
964
When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
964
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
01:11Renal Failure: Dose Adjustments
79
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
79